Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.41 CAD 0.71% Market Closed
Market Cap: 140.3m CAD

Cardiol Therapeutics Inc
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cardiol Therapeutics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Depreciation & Amortization
CA$124.5k
CAGR 3-Years
-17%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Depreciation & Amortization
$1.2B
CAGR 3-Years
-4%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
Canopy Growth Corp
TSX:WEED
Depreciation & Amortization
CA$40.7m
CAGR 3-Years
-27%
CAGR 5-Years
-22%
CAGR 10-Years
43%
Sundial Growers Inc
NASDAQ:SNDL
Depreciation & Amortization
CA$56.1m
CAGR 3-Years
29%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Depreciation & Amortization
$13.1m
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
60%
K
Knight Therapeutics Inc
TSX:GUD
Depreciation & Amortization
CA$55.5m
CAGR 3-Years
-3%
CAGR 5-Years
17%
CAGR 10-Years
86%
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
140.3m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
2.8 CAD
Undervaluation 50%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
124.5k CAD

Based on the financial report for Sep 30, 2025, Cardiol Therapeutics Inc's Depreciation & Amortization amounts to 124.5k CAD.

What is Cardiol Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-11%

Over the last year, the Depreciation & Amortization growth was -68%. The average annual Depreciation & Amortization growth rates for Cardiol Therapeutics Inc have been -17% over the past three years , -11% over the past five years .

Back to Top